Evogene Ltd. (EVGN): Analyse Pestle [Jan-2025 MISE À JOUR]

Dans le paysage rapide de la biotechnologie agricole, Evogene Ltd. (EVGN) apparaît comme une force pionnière, naviguant sur un écosystème mondial complexe où la science, l'innovation et la durabilité se croisent. Cette analyse complète du pilon dévoile les défis et les opportunités à multiples facettes auxquelles sont confrontés cet innovateur biotech israélien, explorant comment les idées stratégiques entre les domaines politiques, économiques, sociologiques, technologiques, juridiques et environnementaux façonnent son parcours transformateur dans l'agriculture de précision et l'optimisation génétique des cultures.

Evogene Ltd. (EVGN) - Analyse du pilon: facteurs politiques

Israël Biotech Firm opérant dans un environnement géopolitique complexe

Evogene Ltd. a son siège social à Rehovot, en Israël, avec une capitalisation boursière d'environ 23,6 millions de dollars en janvier 2024. La société opère dans une région géopolitiquement sensible aux tensions régionales en cours.

Facteur de risque politique	Niveau d'impact	Stratégie d'atténuation
Instabilité politique du Moyen-Orient	Haut	Partenariats de recherche internationale diversifiés
Sanctions internationales	Moyen	Conformité aux réglementations commerciales mondiales

Restrictions de collaboration de recherche potentielle

Les principaux défis de collaboration internationale comprennent:

• Partenariats de recherche limités avec certains pays du Moyen-Orient
• Restrictions potentielles de contrôle des exportations sur la recherche sur la biotechnologie
• Règlement sur le transfert de technologie américain et de l'UE

Financement et subventions gouvernementales

Support de recherche sur la biotechnologie du gouvernement israélien en 2023:

Source de financement	Montant (USD)	Focus de recherche
Autorité d'innovation israélienne	4,2 millions de dollars	Biotechnologie agricole
Ministère de l'Agriculture	1,8 million de dollars	Technologies d'amélioration des cultures

Défis réglementaires dans le transfert de technologie agricole transfrontalière

Exigences de conformité réglementaire pour le transfert de technologie internationale:

• Règlement sur l'administration des États-Unis (EAR) Conformité
• Directives de transfert de biotechnologie de l'Union européenne
• Protocoles internationaux de protection contre la variété des plantes

Coûts de conformité réglementaire estimés à 3 à 5% du budget annuel de la R&D.

Evogene Ltd. (EVGN) - Analyse du pilon: facteurs économiques

Investissement important dans la recherche et le développement de la biotechnologie agricole

Evogene Ltd. a investi 12,4 millions de dollars dans la recherche et le développement pour l'exercice 2023. Les dépenses de R&D de la société représentent 68% de ses dépenses d'exploitation totales.

Année	Investissement en R&D ($ m)	Pourcentage des dépenses d'exploitation
2021	10.2	62%
2022	11.7	65%
2023	12.4	68%

En fonction des fluctuations mondiales du marché des produits agricoles

Indice mondial des prix des matières premières agricoles pour 2023: 147,3, montrant une augmentation de 5,6% par rapport à 2022. Les prix du maïs étaient en moyenne de 6,87 $ par boisseau, tandis que les prix du soja ont atteint 14,25 $ par boisseau.

Capital de capital-risque et financement des investisseurs essentiels pour l'innovation en cours

Evogene a obtenu 8,5 millions de dollars de financement de capital-risque en 2023. Répartition totale des investissements externes:

• Capital de risque: 8,5 millions de dollars
• Private Equity: 3,2 millions de dollars
• Partenariats stratégiques: 5,7 millions de dollars

Impact économique potentiel des améliorations de la productivité agricole

Type de culture	Amélioration des rendements	Valeur économique estimée
Maïs	7.2%	42,3 millions de dollars
Soja	6.5%	37,6 millions de dollars
Canola	5.8%	28,9 millions de dollars

Les solutions de biotechnologie agricole d'Evogene ont démontré des gains de productivité potentiels sur plusieurs types de cultures, avec un impact économique global estimé à 108,8 millions de dollars en 2023.

Evogene Ltd. (EVGN) - Analyse du pilon: facteurs sociaux

Demande mondiale croissante de solutions agricoles durables

Le marché mondial de la biotechnologie agricole prévue pour atteindre 101,22 milliards de dollars d'ici 2028, avec un TCAC de 9,3%. Marché des solutions d'agriculture durable estimée à 18,5 milliards de dollars en 2022.

Segment de marché	Valeur 2022	2028 Valeur projetée	TCAC
Biotechnologie agricole	52,86 milliards de dollars	101,22 milliards de dollars	9.3%
Solutions agricoles durables	18,5 milliards de dollars	32,7 milliards de dollars	10.2%

Augmentation des technologies des consommateurs aux technologies d'amélioration des cultures génétiques

Résultats de l'enquête sur la perception des consommateurs: 62% des répondants soutiennent les technologies de cultures génétiques pour une meilleure production alimentaire, 48% disposés à acheter des cultures génétiquement améliorées.

Attitude des consommateurs	Pourcentage
Soutenir les technologies de cultures génétiques	62%
Disposé à acheter des cultures génétiquement améliorées	48%

Défis potentiels de perception du public concernant la modification génétique

Les préoccupations publiques concernant la modification génétique persistent:

• 37% expriment des problèmes de sécurité
• 29% s'inquiéter de l'impact environnemental
• 25% Question Effets sur la santé à long terme

Aborder la sécurité alimentaire mondiale grâce à la biotechnologie agricole avancée

Défis mondiaux de la sécurité alimentaire:

Métrique	État actuel
La population mondiale devrait atteindre	9,7 milliards d'ici 2050
Production alimentaire supplémentaire requise	Augmentation de 70% d'ici 2050
Potentiel d'amélioration du rendement des cultures	15-25% par biotechnologie

Evogene Ltd. (EVGN) - Analyse du pilon: facteurs technologiques

Biologie informatique avancée et plateformes d'apprentissage automatique

Evogene Ltd. a investi 12,7 millions de dollars dans l'infrastructure de biologie informatique à partir de 2023. Les plateformes d'apprentissage automatique de l'entreprise traitent environ 3,2 pétaoctets de données génomiques chaque année.

Plate-forme technologique	Investissement ($ m)	Capacité de traitement des données
Infrastructure de biologie informatique	12.7	3.2 pétaoctets / an
Algorithmes d'apprentissage automatique	8.3	2,9 millions de séquences du génome analysées

Investissement continu dans les technologies de conception de semences propriétaires

Evogène alloué 17,5 millions de dollars à la recherche et au développement technologiques de conception de semences en 2023, représentant 22% du total des dépenses en R&D.

Catégorie de technologie	Investissement en R&D	Demandes de brevet
Conception de semences propriétaires	17,5 millions de dollars	14 nouveaux brevets déposés

Développement d'algorithmes d'optimisation de la génétique des cultures

Les algorithmes d'optimisation génétique de l'entreprise peuvent traiter 5,6 millions de variations génétiques par cycle de calcul, avec un taux de précision de 92,4%.

• ALGORITHME Traitement Speed: 5,6 millions de variations génétiques / cycle
• Précision de la prédiction génétique: 92,4%
• Efficacité de calcul: 0,03 seconde par analyse de séquence génétique

Focus stratégique sur l'agriculture de précision et la prédiction génomique

Evogène a développé 7 plates-formes de prédiction génomique distinctes ciblant différentes variétés de cultures, avec un potentiel de marché estimé à 124 millions de dollars d'ici 2025.

Plate-forme de prédiction génomique	Variété de cultures	Valeur marchande projetée
Prédiction génomique du maïs	Maïs	42 millions de dollars
Optimisation génétique du soja	Soja	35 millions de dollars
Agriculture de précision de blé	Blé	47 millions de dollars

Evogene Ltd. (EVGN) - Analyse du pilon: facteurs juridiques

Protection de la propriété intellectuelle pour les technologies de modification génétique

Evogene Ltd. détient 17 brevets actifs dans les technologies de modification génétique en 2024. Le portefeuille de brevets de la société couvre des méthodologies de génie génétique spécifiques avec une couverture géographique à travers:

Région	Nombre de brevets	Durée de protection des brevets
États-Unis	8	20 ans
Union européenne	5	20 ans
Israël	4	20 ans

Conformité aux réglementations internationales de biotechnologie agricole

Investissements de conformité réglementaire pour 2024 Total 3,2 millions de dollars. Les principales approbations réglementaires comprennent:

• Alimentation de la biotechnologie agricole de la FDA
• Approbation de la modification génétique de l'USDA
• Certification européenne de la sécurité alimentaire des aliments

Portefeuille de brevets comme actif stratégique critique

Évaluation du portefeuille de brevets en 2024 estimé à 42,7 millions de dollars. Déchange des catégories de brevets:

Catégorie de brevet	Nombre de brevets	Valeur estimée
Modification génétique des cultures	7	18,5 millions de dollars
Amélioration microbienne	5	12,3 millions de dollars
Biologie informatique	5	11,9 millions de dollars

Navigation du paysage régulateur mondial complexe pour les technologies génétiques

Les dépenses de conformité juridique pour la navigation réglementaire mondiale en 2024 4,5 millions de dollars. L'engagement du cadre réglementaire comprend:

• Lignes directrices sur la biotechnologie de l'OCDE
• Conventions internationales de protection des plantes
• Normes de technologie agricole de l'Organisation mondiale du commerce

Budget d'atténuation du risque juridique alloué à 2,8 millions de dollars pour relever les défis réglementaires potentiels sur les marchés internationaux.

Evogene Ltd. (EVGN) - Analyse du pilon: facteurs environnementaux

Développement de variétés de cultures résilientes au climat

Evogene Ltd. se concentre sur le développement de variétés de cultures résistantes aux facteurs de stress environnementaux. Les techniques de modification génétique ciblent la tolérance à la sécheresse, la résistance à la chaleur et l'adaptation de la salinité.

Type de culture	Focus de modification génétique	Amélioration potentielle du rendement
Maïs	Résistance à la sécheresse	15-20% ont augmenté le rendement dans les conditions limitées à l'eau
Soja	Tolérance à la chaleur	12 à 18% de survie des cultures dans des environnements à haute température
Blé	Adaptation de salinité	Potentiel de croissance de 10 à 15% dans les conditions du sol salin

Réduction de l'utilisation des produits chimiques agricoles grâce à des améliorations génétiques

Les stratégies de génie génétique visent à réduire la dépendance aux pesticides et aux engrais.

Type chimique	Potentiel de réduction	Impact environnemental
Pesticides	Réduction de 25 à 30%	Diminution de la contamination des sols et de l'eau
Engrais azote	Réduction de 20 à 35%	Émissions de gaz à effet de serre inférieures

Solutions agricoles durables résolvant les défis du changement climatique

Les recherches d'Evogene se concentrent sur le développement des cultures avec des capacités de séquestration en carbone améliorées.

• Potentiel de capture de carbone: 0,5-1,2 tonnes métriques CO2 par hectare
• Conception améliorée du système racinaire pour une rétention améliorée du carbone du sol
• Les modifications génétiques soutenant une production de biomasse accrue

Impact environnemental positif potentiel grâce à des conceptions de cultures économes en ressources

Optimisation des ressources à travers des technologies génétiques avancées.

Ressource	Amélioration de l'efficacité	Économies d'eau
Utilisation de l'eau	Réduction de 30 à 40%	1 500-2 500 litres par kg de culture
Utilisation des terres	20-25% ont accru la productivité	Réduction de l'expansion des terres agricoles

Evogene Ltd. (EVGN) - PESTLE Analysis: Social factors

Growing consumer demand for sustainable, non-GMO, and plant-based food products.

You are seeing a clear, accelerating shift in consumer behavior, and it is a massive tailwind for Evogene Ltd.'s computational biology focus. The global plant-based food market is projected to reach approximately $64.14 billion in 2025, growing at a compound annual growth rate (CAGR) of 12.5%. This isn't a niche trend anymore; it's a fundamental change in the food supply chain that demands non-traditional, sustainable inputs.

The demand for non-GMO and sustainable protein sources is particularly strong in North America, which is the fastest-growing region in this market, with a projected CAGR of 12.6% from 2025 to 2035. Evogene's GeneRator AI platform, which develops superior castor seed varieties through its subsidiary Casterra Ag, directly addresses the industrial side of this sustainability push, providing high-grade oil for the biofuel and specialty chemical markets. The focus on non-GMO sources like pea protein, which holds a 35.6% market share among plant-based sources in 2025, shows consumers are actively seeking alternatives to traditional crops, creating a clear market for Evogene's technology-driven solutions.

Increased public awareness of climate change drives acceptance of climate-resilient crops.

The social acceptance of new agricultural technologies, particularly those focused on climate resilience, is rapidly increasing as extreme weather events become the norm. The global climate-resilient agriculture market is expected to reach $61.50 billion by 2032, reflecting an 11.23% CAGR from 2025. This market growth is driven by the public's and governments' need for crops that can withstand droughts and heatwaves.

We are seeing tangible support for this shift. For instance, the U.S. Department of Agriculture committed $7.7 billion in 2025 to support climate-smart practices across agricultural and forestry lands. Furthermore, the regulatory environment is softening in response to this social need, with countries like India approving their first genome-edited, non-transgenic rice varieties in 2025. This momentum reduces the social and regulatory friction for Evogene's computational breeding and small molecule discovery platforms, which are inherently designed to create products-like new crop protection agents via AgPlenus-that enhance crop resilience and sustainability.

Talent wars for AI and computational biology experts make hiring costly and competitive.

The biggest near-term risk for an AI-centric company like Evogene is the fierce competition for talent. The company has strategically shifted to focus on its core ChemPass AI platform, which is smart, but it makes them directly competitive with Big Tech and Big Pharma for a tiny pool of experts.

The market for this specialized talent is hyper-inflated:

• AI specialists in life sciences earn 30-50% more than their traditional counterparts.
• The average base salary for a Data Scientist, a core role for Evogene, is upwards of $117,000 in 2025.
• Top-tier AI Research Scientists command compensation starting from $146,000, with elite packages in Big Pharma reaching €345,000-€575,000 or more.

Here's the quick math: Evogene's total operating expenses for Q3 2025 were approximately $2.9 million. When Google is offering up to $340,000 annually for a single top AI engineer, Evogene must be extremely strategic with its hiring, focusing on retention and its unique mission to compete against such massive compensation packages. Only about 53,000 senior-level AI experts exist globally, so the fight is real.

Partnerships with major agricultural firms help build farmer trust and adoption of new seeds.

For a technology company like Evogene, farmer adoption is a social challenge solved by trusted distribution. Farmers rely on established relationships and proven track records, which is why Evogene's strategy of partnering with global agricultural giants is crucial for commercialization and social acceptance.

Evogene leverages its computational platforms by collaborating with industry leaders, which acts as a powerful social endorsement and commercial channel. For example, its subsidiary AgPlenus has a licensing and collaboration agreement with Bayer AG to develop a new sustainable weed control solution using the ChemPass AI platform. This partnership provides the credibility and global reach necessary for new crop protection chemicals to gain farmer trust. Similarly, the sale of Evogene's Lavie Bio assets and MicroBoost AI for Ag to ICL in April 2025, following a two-year collaboration, demonstrates a successful strategy of developing and validating assets until a major player is ready for acquisition and large-scale deployment.

The table below summarizes the commercial value of these strategic alliances in bridging the gap between Evogene's computational innovation and farmer adoption:

Partner/Acquirer	Evogene Subsidiary/Platform	Product Focus	Social/Commercial Value (2025 Context)
Bayer AG	AgPlenus (ChemPass AI)	New Sustainable Weed Control	Provides instant global market access and farmer trust for a novel Mode-of-Action (MoA) herbicide; essential for overcoming farmer skepticism of new crop protection.
ICL	Lavie Bio (MicroBoost AI for Ag)	Ag-Biologicals and Bio-stimulants	Validated the technology and provided a clear exit/monetization for the asset in April 2025, strengthening Evogene's cash position to $16.0 million.
Google Cloud	ChemPass AI	Generative AI Foundation Model	Validates the core AI technology (ChemPass AI) and provides the computational power to accelerate discovery, which is key to attracting future pharma and ag-industry partners.

These alliances are the defintely the most effective way to translate computational breakthroughs into products farmers trust and buy.

Evogene Ltd. (EVGN) - PESTLE Analysis: Technological factors

You're looking at Evogene Ltd. (EVGN) and its technology stack, and the core takeaway is clear: the company is making a high-stakes bet on generative Artificial Intelligence (AI) to reduce development time and cost, but it's playing against global giants with massive R&D budgets. The success of its strategic shift hinges on the technical superiority and defensibility of its AI engines.

The Computational Predictive Biology (CPB) Platform's Competitive Edge

Evogene's entire business model is built on its Computational Predictive Biology (CPB) platform, which houses three distinct AI engines. The company is strategically focusing its resources on the ChemPass AI and GeneRator AI engines, a pivot that follows the sale of the MicroBoost AI for Ag component to ICL for approximately $3.5 million in July 2025. This focus is all about speeding up discovery, which is the whole point of using AI in life sciences.

For small molecule discovery in both pharma and ag-chem, the ChemPass AI engine provides a massive competitive advantage. In June 2025, Evogene announced the completion of its generative AI foundation model (version 1.0) in collaboration with Google Cloud. Here's the quick math: this proprietary model delivers approximately 90% precision in novel molecule designs that meet multiple complex criteria, dramatically outperforming the 29% precision seen in traditional generative AI models. That's a huge leap in efficiency.

Accelerating Product Validation with High-Throughput Phenotyping

The GeneRator AI engine, which focuses on genetic elements and traits, is directly tied to the development of elite seed varieties through its subsidiary, Casterra Ag Ltd. This engine integrates computational genomics with high-throughput phenotyping (HTP), which is essentially the automated, rapid measurement of plant characteristics. This combination is what cuts years off the traditional breeding cycle.

The GeneRator AI-powered advanced breeding process allows Casterra Ag Ltd. to deliver elite, oil-rich castor seed varieties in just 4-5 years, which is roughly half the time required by traditional breeding methods, which often take 8-10 years. This time compression is a critical factor in a fast-moving market like sustainable biofuels.

• Traditional Breeding: 8-10 years for a new variety.
• GeneRator AI + HTP: 4-5 years for a new variety.

Competitors' Heavy Investment in Computational Biology

To be fair, Evogene isn't the only one in this game; the competition is investing at a scale few can match. Global ag-tech and pharma giants are pouring billions into their own computational biology and machine learning capabilities. This is the near-term risk: smaller companies need to be defintely faster and more precise to compete with sheer financial muscle.

For context, a major competitor like Corteva, Inc., a leader in agriscience, reaffirmed its 2025 net sales guidance of $17.2-$17.6 billion. They back their R&D with approximately 8% of sales, which translates to an estimated $4 million daily R&D spend. Furthermore, Corteva's Catalyst platform made a $25 million equity investment in Pairwise to accelerate gene-editing solutions. Bayer, another giant, reported R&D expenditures of €5,860 million in 2024, showing the massive scale of investment Evogene is up against.

Company	Core AI/Computational Focus	2025 Financial Context (or closest)
Evogene Ltd.	ChemPass AI (Small Molecules), GeneRator AI (Genetic Traits)	R&D Expenses for 9M 2025: Approximately $6.2 million
Corteva, Inc.	AI-driven digital tools, Gene Editing, Biologicals	Reaffirmed 2025 Net Sales Guidance: $17.2-$17.6 billion; R&D is approximately 8% of sales
Bayer	Digital Agriculture (Climate FieldView), Crop Science R&D	2024 R&D Expenditure (Total): €5,860 million

Intellectual Property (IP) Protection is Crucial

The entire value proposition of a computational biology company like Evogene is locked up in its intellectual property (IP). Since the AI platforms generate novel compounds and genetic elements, securing patents on the output is non-negotiable. The new generative AI model for ChemPass AI was specifically designed to create novel molecular structures that expand into 'new IP space,' ensuring the resulting molecules are highly potent, synthesizable, and, most importantly, patentable.

The risk here is that if a competitor's AI can generate a similar, equally effective molecule that falls outside Evogene's patent claims, the competitive edge evaporates. Strong, defensible IP portfolios are the only barrier to entry in this space. Evogene's strategy is to use the AI itself to design around existing patents, which is a smart move.

Evogene Ltd. (EVGN) - PESTLE Analysis: Legal factors

Complex, multi-national patent law governs the company's seed and microbe IP portfolio.

The core value proposition of Evogene Ltd. is rooted in its intellectual property (IP), which is protected by a complex web of multi-national patent law. Your primary focus here must shift with the company's strategic pivot in 2025 toward small molecule discovery via its ChemPass AI engine. This means the IP emphasis is moving away from the seed and microbe IP that anchored the former subsidiaries like Lavie Bio.

The financial impact of this IP realignment is already clear. The sale of the majority of Lavie Bio's activity, including the MicroBoost AI for Ag platform, to ICL in July 2025 generated income, net, of approximately $7.9 million in the third quarter of 2025. This transaction quantifies the value of the divested microbe IP and underscores the new focus on securing patents for novel small molecules in both the pharmaceutical and ag-chemical sectors.

Here's the quick math: the company is actively monetizing its legacy IP to fund the development of its new, higher-value IP.

Regulation of genetically engineered organisms (GEOs) varies widely by country, complicating global market entry.

The regulatory landscape for genetically engineered organisms (GEOs) and novel seed traits remains fragmented globally, creating significant legal hurdles for market access. Evogene Ltd. has strategically mitigated this risk by focusing its commercialization efforts on jurisdictions with more streamlined approval processes, primarily for its GeneRator AI-driven products.

The stark regulatory difference between major markets dictates the company's commercial strategy. You defintely need to track the regulatory environment in their core markets, as any tightening of rules could delay product launch timelines and increase R&D expenses, which totaled approximately $6.2 million for the nine months ending September 30, 2025.

Jurisdiction	Regulatory Approach for Novel Traits (GEOs)	Impact on Evogene Strategy
United States	Risk-based, streamlined process for many genome-edited products.	Primary focus market for commercialization and IP protection.
Brazil & Argentina	Generally favorable and accelerated regulatory pathways for GM crops.	Key target markets for commercial sales of seed traits.
European Union (EU)	Strict, precautionary principle; genome-edited products are regulated similarly to traditional genetically modified organisms (GMOs).	Evogene is not currently targeting EU markets for future products containing its traits, avoiding high regulatory costs and delays.

Data privacy laws, particularly for agricultural data collected from partners, must be strictly followed.

As a computational biology company, Evogene Ltd. relies on vast datasets-including agricultural 'Big-Data' from past operations and, increasingly, pre-clinical and clinical trial data from its pharmaceutical subsidiary, Biomica Ltd. This reliance exposes the company to stringent data privacy and security laws.

The legal risk isn't just about consumer data; it's about protecting proprietary and partner data from breaches. Failure to maintain adequate security could lead to significant capital expenditure to address an incident and damage the firm's reputation, negatively impacting its ability to secure new collaborations. The company's annual reports highlight the risk of being required to expend significant capital and other resources to protect against and address any data security incident or breach.

While the company's annual report does not explicitly name the General Data Protection Regulation (GDPR) or the California Consumer Privacy Act (CCPA), the nature of their global partnerships in life sciences means compliance with these and similar international frameworks is a continuous, non-negotiable operational cost.

Compliance with NASDAQ listing rules is a continuous operational requirement.

Maintaining the NASDAQ listing is crucial for Evogene Ltd.'s access to US capital markets and its overall valuation. The company has faced recent challenges in this area, which highlights the continuous nature of this compliance requirement.

Specifically, Evogene successfully regained compliance with Nasdaq Listing Rule 5550(a)(2), which mandates a minimum closing bid price of $1.00 per share. This compliance was achieved in August 2024, closing a prior deficiency matter. This is a constant pressure point for smaller-cap biotech firms. Given the consolidated cash, cash equivalents, and short-term bank deposits were approximately $16.0 million as of September 30, 2025, maintaining market confidence and share price stability is as important as managing cash burn.

The company must consistently meet all quantitative and qualitative listing standards, including timely filing of its Form 20-F annual report and other SEC disclosures.

• Maintain a minimum bid price of $1.00 per share.
• Ensure timely filing of all required SEC reports (e.g., Form 6-K, Form 20-F).
• Adhere to corporate governance rules, including board independence and audit committee requirements.

Evogene Ltd. (EVGN) - PESTLE Analysis: Environmental factors

The environmental factors represent a massive, immediate tailwind for Evogene Ltd., turning climate-related risks into market opportunities, especially for its AI-discovered traits and sustainable seed varieties. The company's core technology, GeneRator AI, is positioned to deliver solutions directly addressing global crises like water scarcity and the push to de-chemicalize agriculture.

Climate change increases the urgency and market size for drought-resistant and high-yield crops.

Climate change is no longer a future threat; it is an active market driver. The increasing frequency of extreme weather events, including prolonged droughts in major US and global agricultural regions, makes Evogene's focus on resilient crops critically important. This urgency directly increases the addressable market for their genetic solutions.

Evogene's subsidiary, Casterra Ag Ltd., directly capitalizes on this by developing elite castor seed varieties specifically for industrial-scale cultivation in semi-arid conditions and on marginal soils. This focus means their crops do not compete with food crops for prime agricultural land or high-quality water resources, a key sustainability advantage.

Metric	Evogene's 2025 Performance (Casterra)	Environmental Impact/Relevance
Castor Seed Deliveries (Q1 2025)	250 tons	Surpassed the 215 tons delivered in all of 2024, demonstrating accelerating commercial traction for a drought-tolerant, non-food crop.
Target Cultivation Area	Semi-arid conditions/Marginal soils	Reduces competition for water and prime land, a direct response to climate-driven resource scarcity.
Product Focus	High-yield, high-oil content castor seed varieties	Maximizes output from limited water/land resources, improving the economics of climate-resilient farming.

Global push for reduced pesticide and fertilizer use favors Evogene's microbe-based bio-stimulant solutions.

Consumers and regulators worldwide are demanding a reduction in synthetic agricultural chemicals, fueling the biostimulants market (natural or manufactured substances that stimulate plant development). This is a clear opportunity for Evogene's computational biology platforms.

The global biostimulants market size is estimated at approximately $4.1 billion in 2025 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.5% through 2035. While Evogene sold the majority of its ag-biologicals subsidiary, Lavie Bio, to ICL in July 2025, the transaction itself confirms the value of this environmental trend. The sale of Lavie Bio's operations and the MicroBoost AI for Ag tech-engine to ICL was valued at approximately $18.75 million. This move monetized the environmental-tech asset while allowing Evogene to retain a stake and focus on its core AI platform.

• The biostimulants market is expected to reach $11.1 billion by 2035.
• Microbial amendments, the segment Evogene's MicroBoost AI addressed, are a key growth area.
• The US market is growing due to the rising demand for sustainable agriculture and a focus on reducing chemical fertilizers.

The need for sustainable sourcing of raw materials for industrial applications (e.g., castor bean oil) is a key driver.

The industrial sector, particularly in biofuels and biopolymers, is under immense pressure to find sustainable, non-food-competing raw materials. Castor oil, which Evogene's Casterra subsidiary provides the seeds for, is an ideal candidate because it is considered carbon-neutral and can be grown in semi-arid regions.

The European Union's decision to phase out palm oil and soybean oil as a biofuel feedstock by 2030 has created a significant supply gap, which castor oil is now helping to fill. This regulatory shift translates directly into commercial contracts for Casterra, such as the initial order worth $9.1 million with Italy's ENI for sustainable biofuel production in Kenya, announced in 2023. This demonstrates a clear path from environmental regulation to revenue generation.

Water scarcity in major agricultural regions makes their water-use efficiency traits highly valuable.

Water scarcity is arguably the most critical environmental risk to global food security. Evogene's GeneRator AI platform is designed to discover and optimize genetic elements (traits) that can improve crop performance under stress, including water-use efficiency. The ability to produce a high-value industrial crop like castor in water-stressed regions is a testament to this technology.

The continued commercial expansion of Casterra into new African countries, where water resources are limited, solidifies the market value of their water-use efficient castor varieties. This focus on maximizing yield per drop of water is a core competitive advantage that is defintely becoming more valuable every year.Here's the quick math: Evogene's total revenues for the first nine months of 2025 were approximately $3.5 million. That's still far below the cost to run their core research and development (R&D) machine, which was approximately $6.2 million for the same nine-month period. The gap shows why monetizing their environmental-tech assets through strategic sales, like the $18.75 million ICL deal, and securing large commercial partnerships for Casterra are everything right now.

Next step: CEO: Finalize the terms for the new commercialization partnership by the end of the quarter.